MedTrace Logo

Exercise-based Cardiac Rehabilitation for the Prevention of Breast Cancer Chemotherapy-induced Cardiotoxicity

NCT03964142 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2023-05-12

No results posted yet for this study

Summary

This project aims to determine whether a comprehensive cardiac rehabilitation program including supervised exercise training is able to prevent cardiotoxicity during treatment with anthracyclines and / or anti-HER-2 antibodies in women with breast cancer. Participants will be randomly allocated to cardiac rehabilitation (intervention group) or conventional management with physical exercise recommendation (control group).

Conditions

Interventions

OTHER

Cardiac rehabilitation

Integrated cardiac rehabilitation program that includes supervised exercise training\*. \* Due to the COVID-19 pandemic, supervised physical exercise training had to be conducted telematically (through live guided training sessions conducted online, with the same design, frequency, and dosage of exercise).

Sponsors & Collaborators

  • Instituto de Salud Carlos III

    collaborator OTHER_GOV

  • Hospital Clinico Universitario de Santiago

    lead OTHER

Principal Investigators

  • Amparo Martínez Monzonís, MD, PhD · Cardiology Department, Hospital Clínico Universitario de Santiago, CIBER-CV

  • Carlos Peña Gil, MD, PhD · Cardiology Department, Hospital Clínico Universitario de Santiago, CIBER-CV

  • José Ramón González Juanatey, MD, PhD · Cardiology Department, Hospital Clínico Universitario de Santiago, CIBER-CV

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
69 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2022-03-30
Completion
2023-01-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03964142 on ClinicalTrials.gov